Doolittle G C, Bodensteiner D C, Skikne B S, Amare M
Department of Medicine, Kansas University Medical Center, Kansas City 66103.
Am J Hematol. 1991 Feb;36(2):144-6. doi: 10.1002/ajh.2830360214.
Five consecutive patients with severe aplastic anemia were treated with antithymocyte globulin followed by cyclosporin A. All received antithymocyte globulin initially, and because of lack of response within a 4 week period, cyclosporin was administered subsequently. Hematologic improvement occurred within four months of initiation of cyclosporin. Four patients no longer require blood product support, while one remains transfusion-dependent. In two patients, thrombocytopenia developed when the cyclosporin was tapered but re-institution of the drug resulted in a prompt improvement of counts. These observations indicate that the sequential use of antithymocyte globulin and cyclosporin may be an effective therapeutic approach in the treatment of severe aplastic anemia.
连续5例重型再生障碍性贫血患者接受抗胸腺细胞球蛋白治疗,随后使用环孢素A。所有患者最初均接受抗胸腺细胞球蛋白治疗,由于4周内无反应,随后给予环孢素。环孢素开始使用后4个月内血液学有改善。4例患者不再需要血液制品支持,而1例仍依赖输血。2例患者在环孢素减量时出现血小板减少,但重新使用该药物后计数迅速改善。这些观察结果表明,抗胸腺细胞球蛋白和环孢素序贯使用可能是治疗重型再生障碍性贫血的有效治疗方法。